Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytek Biosciences, Inc. (Nasdaq: CTKB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer on the Nasdaq Global Select Market. These documents help investors and analysts understand Cytek’s financial condition, operating results and governance as a cell analysis solutions company focused on Full Spectrum Profiling™ (FSP®) flow cytometry instruments, reagents and services.
Cytek submits Form 10-Q quarterly reports and Form 10-K annual reports, which include details on revenue from products, services and reagents, gross margins, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as information on cash and marketable securities. These filings also discuss risk factors, market conditions and other elements relevant to its analytical laboratory instrument manufacturing business.
The company also files Form 8-K current reports to disclose material events. Recent 8-K filings have covered quarterly financial results under Item 2.02 (Results of Operations and Financial Condition) and outcomes of the annual meeting of stockholders under Item 5.07, including votes on director elections, executive compensation and ratification of the independent registered public accounting firm.
In addition, investors can review exhibits attached to these filings, such as press releases furnished as Exhibit 99.1, which provide narrative context for the numbers reported. Over time, the filings record Cytek’s progress in areas such as recurring revenue growth from services and reagents, expansion of its installed instrument base and capital allocation decisions.
On Stock Titan, Cytek’s SEC filings are updated in near real time from the EDGAR system. AI-powered summaries highlight key points from lengthy 10-K and 10-Q reports, and help users quickly identify information on revenue composition, operating trends and risk disclosures. The page also makes it easier to locate Form 4 and other insider-related filings when available, supporting research into trading activity and governance practices at CTKB.
Form 4 snapshot: On 18 June 2025 Cytek Biosciences (CTKB) reported that director Michael Holder received two equity awards – 43,973 Restricted Stock Units (RSUs) and 23,809 non-qualified stock options – both coded “A” for acquisition.
Key terms:
- RSUs: One RSU converts into one common share; no cash paid.
- Options: Exercise price set at $3.07, indicating the share price on grant date.
- Vesting for both awards: 100% on the earlier of 18 June 2026 or the 2026 annual meeting (if held in June 2026).
Post-transaction ownership: Holder now directly holds 43,973 RSUs and 23,809 options, representing a potential 67,782 new shares if fully vested and exercised. No sales, dispositions or open-market purchases were disclosed.
Investor takeaway: The filing reflects routine board compensation, aligns the director’s interests with shareholders for at least the next year and introduces only minor potential dilution relative to the company’s total shares outstanding. No information affecting earnings, cash flow or strategy was provided.